HIMS

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

High

33.890

Open

33.730

VWAP

32.83

Vol

38.98M

Mkt Cap

7.40B

Low

31.750

Amount

1.28B

EV/EBITDA(TTM)

88.52

Total Shares

214.79M

7.54B

EV/OCF(TTM)

30.02

P/S(TTM)

5.62

Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. The Company’s digital platform offers access to a provider network, a clinically focused electronic medical record system, digital prescriptions and cloud pharmacy fulfillment. Its digital platform provides access to treatments for a range of conditions, including those related to sexual health, hair loss, dermatology, mental health and weight loss. The Company connects patients to licensed healthcare professionals who can prescribe medications when appropriate. In addition, the Company also offers access to a range of health and wellness products designed to meet individual needs, which includes curated prescription and non-prescription products. Its Hims & Hers mobile application enables consumers to access a range of educational programs, wellness content, community support and other services that promote lifelong health and wellness.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

536.45M

+92.85%

567.06M

+79.65%

592.95M

+47.66%

Estimates Revision

The market is revising Upward the revenue expectations for Hims & Hers Health, Inc. (HIMS) for FY2025, with the revenue forecasts being adjusted by 11.63% over the past three months. During the same period, the stock price has changed by -2.53%.

Revenue Estimates for FY2025

Revise Upward

+11.63%

In Past 3 Month

Stock Price

Go Down

-2.53%

In Past 3 Month

13 Analyst Rating

38.28% Upside

Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 45.77 USD with a low forecast of 22.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

6 Hold

2 Sell

Hold

38.28% Upside

Current: 33.100

Low

22.00

Averages

45.77

High

85.00

38.28% Upside

Current: 33.100

Low

22.00

Averages

45.77

High

85.00

TD Cowen

Jonna Kim

Strong Buy

Hold

Downgrades

$44 → $30

2025-04-29

New

Reason

TD Cowen

Jonna Kim

Price Target

$44 → $30

2025-04-29

New

Downgrades

Strong Buy

Hold

Reason

TD Cowen downgraded Hims & Hers to Hold from Buy with a price target of $30, down from $44. The shares could be range-bound with weight loss drugs no longer in shortage, the analyst tells investors in a research note. The firm believes share upside to the remainder of the year could be limited after Hims & Hers' "strong" Q1 as compounded GLP-1s are no longer offered beyond May 22. Management's weight loss revenue guide of $725M for the year could prove to be too optimistic if current GLP-1 users do not switch into Liraglutide or oral medications and prospective weight loss users opt for GLP-1 options elsewhere, adds TD. Further, the firm believes Hims & Hers' competitive landscape is intensifying.

Morgan Stanley

Craig Hettenbach

Hold

Maintains

$60 → $40

2025-04-29

New

Reason

Morgan Stanley

Craig Hettenbach

Price Target

$60 → $40

2025-04-29

New

Maintains

Hold

Reason

Morgan Stanley lowered the firm's price target on Hims & Hers to $40 from $60 and keeps an Equal Weight rating on the shares. Survey data points to solid underlying trends in the business and the stock is "beginning to look interesting following a sharp correction," the analyst tells investors. However, the key to reversing negative sentiment will be demonstrating continued momentum in the core business and gaining visibility into weight loss revenue, the analyst added.

B of A Securities

Allen Lutz

Sell

Maintains

$22 → $26

2025-04-29

New

Reason

B of A Securities

Allen Lutz

Price Target

$22 → $26

2025-04-29

New

Maintains

Sell

Reason

Citigroup

Daniel Grosslight

Strong Sell

Maintains

$27 → $25

2025-04-25

Reason

Citigroup

Daniel Grosslight

Price Target

$27 → $25

2025-04-25

Maintains

Strong Sell

Reason

Citi lowered the firm's price target on Hims & Hers to $25 from $27 and keeps a Sell rating on the shares. The firm also added a "downside 30-day short-term view" on the shares. Citi expects Hims & Hers will reported "another significant beat and raise" quarter, largely driven by GLP-1 strength. However, this is unlikely to drive the stock higher, the analyst tells investors in a research note. Rather, Citi suspects the stock will trade down again on another sequential slowdown in core revenue with concerns around Hims & Hers' personalized GLP-1 strategy, a weakening consumer, and potential pharma tariffs all weighing on investor sentiment.

Truist Securities

Jailendra Singh

Hold

Maintains

$39 → $33

2025-04-10

Reason

Truist Securities

Jailendra Singh

Price Target

$39 → $33

2025-04-10

Maintains

Hold

Reason

Truist analyst Jailendra Singh lowered the firm's price target on Hims & Hers to $33 from $39 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in the Healthcare IT industry. The industry is typically shielded from macro uncertainty, but tariffs and concerns around an economic slowdown have created broader market uncertainty, which is never good for a high-beta highly volatile group like HCIT/Digital Health/Payviders, the analyst tells investors in a research note. Truist adds that while HCIT companies may not be directly exposed to new tariffs, several of these companies serve end markets - hospitals, pharma, etc. - which are likely to see either some direct impact on their supply chain costs or could decide to slow down on their investments.

B of A Securities

Allen Lutz

Sell

Maintains

$21 → $22

2025-03-18

Reason

B of A Securities

Allen Lutz

Price Target

$21 → $22

2025-03-18

Maintains

Sell

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Hims & Hers Health Inc (HIMS.N) is 51.57, compared to its 5-year average forward P/E of -10.25. For a more detailed relative valuation and DCF analysis to assess Hims & Hers Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.25

Current PE

51.57

Overvalued PE

37.56

Undervalued PE

-58.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.28

Current EV/EBITDA

25.29

Overvalued EV/EBITDA

41.03

Undervalued EV/EBITDA

-40.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.20

Current PS

3.35

Overvalued PS

5.91

Undervalued PS

0.49